ArticleFrontiers in immunology2025
Unveiling the novel value of TREM1 in the proneural-mesenchymal transition of glioma via tumor-associated macrophages.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unveiling the novel role of PGAM5 in rewiring metabolism through PI3K/AKT/mTOR signaling in acute myelogenous leukemia.Scientific reports · 2026Article
- Integrated Pan-Cancer, Single-Cell, and Spatial Transcriptomic Analyses Identify ZDHHC12 as a Biomarker Associated with Macrophage Infiltration and the Immune Landscape in Glioma.Journal of Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor-associated macrophages (TAMs) constitute the most abundant immune cell population in the glioblastoma (GBM) tumor microenvironment. These macrophages critically influence multiple pathological processes in GBM, including recurrence, drug resistance, and immune evasion. However, the role of TREM1 in mediating proneural-to-mesenchymal transition (PMT) in TAMs remains unclear. Methods: Single-cell RNA sequencing analysis of 24,366 cells from seven GBM patients identified nine distinct cellular populations, including TAMs and malignant cells. Deconvolution analysis of TCGA mRNA-seq data complemented these findings. Differential expression analysis, weighted gene co-expression network analysis, and LASSO-Cox regression consistently identified TREM1 in TAMs as a PMT-associated biomarker. A co-culture system demonstrated TREM1's influence on GBM cell malignancy and PMT progression Results: High TAM infiltration correlated significantly with poor clinical outcomes in GBM patients. Integrated scRNA-seq and mRNA-seq analyses established TREM1 in TAMs as a key PMT biomarker. LP17-mediated TREM1 inhibition attenuated PMT through modulation of the TLR4/PI3K/AKT/mTOR pathway and reduced tumor growth Conclusion: TREM1 functions as an oncogenic biomarker in TAMs that drives GBM PMT via the TLR4/PI3K/AKT/mTOR axis, with inhibition of TREM1 demonstrating therapeutic potential in both ex vivo and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.